Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.325 +0.205 (+2.25%)
Streaming Delayed Price Updated: 2:32 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 790,764
Open 9.150
Bid (Size) 9.320 (300)
Ask (Size) 9.330 (200)
Prev. Close 9.120
Today's Range 9.150 - 9.645
52wk Range 4.155 - 11.64
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors. ↗
Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir (VIR) Q1 2026 Earnings Call Transcript ↗
Vir (VIR) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+57.0%
+57.0%
1 Month
-1.8%
-1.8%
3 Month
+28.1%
+28.1%
6 Month
+73.6%
+73.6%
1 Year
+75.9%
+75.9%

More News

Read More
News headline image
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
7 Bull Flag Setups Found With the ChartMill Stock Screener ↗
Via Chartmill
VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick ↗
Via Chartmill
Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates ↗
Via Chartmill
News headline image
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
From Vir Biotechnology
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
News headline image
Vir Biotechnology to Participate in Upcoming Investor Conferences
From Vir Biotechnology, Inc.
Via Business Wire
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Proposed Public Offering of Common Stock
From Vir Biotechnology, Inc.
Via Business Wire
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
Via Stocktwits
News headline image
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? ↗
Via Stocktwits
Topics Earnings
News headline image
Vir Biotechnology (VIR) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?
Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
What is the current price of Vir Biotechnology, Inc. - Common Stock?
The current price of Vir Biotechnology, Inc. - Common Stock is 9.325
When was Vir Biotechnology, Inc. - Common Stock last traded?
The last trade of Vir Biotechnology, Inc. - Common Stock was at 05/11/26 02:32 PM ET
What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
The market capitalization of Vir Biotechnology, Inc. - Common Stock is 1.25B
How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
Vir Biotechnology, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.